RETRACTED: Tirzepatide and exercise training in obesity
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: The purpose of this study was to investigate the effects of 6 weeks of resistance training (RT) combined with aerobic training (AT) and Tirzepatide supplementation on lipid profiles, insulin resistance, anthropometric characteristics and physical fitness in prediabetic obese soldiers. METHODS: 61 obese men were randomly divided into six groups: Placebo; Tirzepatide 5 mg (T5); Tirzepatide 2.5 mg (T2.5); Hypertrophy, Strength, Power-Circuit Training+Placebo (Ex+P); Hypertrophy, Strength, Power-Circuit Training+Tirzepatide 5 mg (Ex+T5); Hypertrophy, Strength, Power-Circuit Training+Tirzepatide 2.5 mg (Ex+T2.5). All training groups performed aerobic training (AT) after resistance training. Subjects trained for six weeks, three sessions per week. Before and after the intervention period, the participants were evaluated for anthropometric measures, body composition [body weight, body mass index (BMI), waist circumference (WC), waist to hip ratio (WHR) and fat mass (FM)], cardiorespiratory fitness (VO2max), and muscle strength (chest press 1RM and leg press 1RM). Blood biochemistry evaluations included triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), fasting blood glucose (FBG), insulin level and insulin resistance (HOMA-IR). To evaluate the differences between the groups, ANCOVA statistical method was used along with Bonferroni’s post hoc test, and the significance level was P < 0.05. R…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Evidence indicates that structured physical activity, particularly resistance training, can mitigate these effects and optimize long-term metabolic outcomes (53–55).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [55]
In the citing paper
“Patients receiving GLP-1RAs experience significant weight loss but are also at increased risk of lean body mass and bone density loss.”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [55]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · cited 1×
“U/mL)]/405 [30].”
Psychophysical bases of perceived exertion
BORG, G. A. V. (1982) · Medicine & Science in Sports & Exercise · doi:10.1249/00005768-198205000-00012 · Cited by 16,580 · cited 1×
“At the end of each phase, the participant was asked to rate the perceived exertion according to the Borg CR-10 scale [28].”
(2016) · The Lancet · doi:10.1016/s0140-6736(16)30054-x · Cited by 5,212 · cited 1×
“The prevalence of obesity has been increasing worldwide [1, 2].”
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 2×
“Tirzepatide injection was administered subcutaneously in the abdomen by a physician once a week using doses of 2.5 mg and 5 mg on a day when the subject did not exercise [25, 26].”
InfluentialBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“GIP inhibits gastric secretory activity, stimulates insulin secretion, and exerts an insulin-like action on adipose tissue that inhibits lipolysis and promotes lipogenesis [39–41].”
Chooi, Y. C., Ding, C., & Magkos, F. (2019) · Metabolism · doi:10.1016/j.metabol.2018.09.005 · Cited by 2,737 · cited 1×
“The prevalence of obesity has been increasing worldwide [1, 2].”
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · cited 1×
“…Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) are hormones released in the intestine in response to the intake of nutrients, and they can stimulate pancreatic beta cells to release insulin, thereby participating in the regulation of glucose homeostasis [13–15].”
(2014) · Journal of the Korean Medical Association · doi:10.5124/jkma.2014.57.11.899 · Cited by 2,566
Bioelectrical impedance analysis—part II: utilization in clinical practice
Kyle, U. G., Bosaeus, I., De Lorenzo, A. D., Deurenberg, P., Elia, M., Manuel Gómez, J., Lilienthal Heitmann, B., Kent-Smith, L., Melchior, J.-C., Pirlich, M., et al. (2004) · Clinical Nutrition · doi:10.1016/j.clnu.2004.09.012 · Cited by 2,350 · cited 1×
“Before the test, the participants were asked to take off their clothes and wear a light and minimal outfit; keep jewelry and other metal and electronic equipment away from themselves and the device; Then wipe their hands and soles of their feet with a dry cloth and then place them on the device [27].”
Inflammatory mechanisms linking obesity and metabolic disease
Saltiel, A. R., & Olefsky, J. M. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92035 · Cited by 2,212
Revision of the Physical Activity Readiness Questionnaire (PAR-Q).
Thomas, S. G., Reading, J., & Shephard, R. J. (1992) · PubMed · Cited by 1,989
(1957) · PubMed · Cited by 1,778
Itani, S. I., Ruderman, N. B., Schmieder, F., & Boden, G. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2005 · Cited by 1,390 · cited 1×
“Accumulation of lipids in the liver, muscles and adipocytes leads to IR [43].”
Thomas, D. T., Erdman, K. A., & Burke, L. M. (2016) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2015.12.006 · Cited by 1,359 · cited 1×
“Three-day food records (two weekdays and one weekend day) were analyzed [24].”
Strength testing—predicting a one-rep max from reps-to-fatigue
Brzycki, M. (1993) · Journal of Physical Education, Recreation & Dance · doi:10.1080/07303084.1993.10606684 · Cited by 1,236 · cited 1×
“When the participants performed less than 10 repetitions, 1RM load was estimated using the Brzycki formula [29].”
The Emerging Risk Factors Collaboration (2011) · The Lancet · doi:10.1016/s0140-6736(11)60105-0 · Cited by 1,216 · cited 1×
“High BMI and waist circumference values are positively associated with T2DM and cardiovascular disease [34, 35].”
Metabolic Syndrome and Risk of Cancer
Esposito, K., Chiodini, P., Colao, A., Lenzi, A., & Giugliano, D. (2012) · Diabetes Care · doi:10.2337/dc12-0336 · Cited by 1,209 · cited 1×
“Obesity increases morbidity, mortality and the risk of serious diseases such as cancer, chronic inflammation, metabolic and cardiovascular diseases [3–5].”
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · cited 1×
“Tirzepatide is a novel medication that activates both GIP and GLP-1 receptors and leads to improved blood-sugar control [16].”
The epidemiology of obesity: the size of the problem
James, W. P. T. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01922.x · Cited by 786 · cited 1×
“Individuals with obesity typically have low cardiorespiratory fitness and relative strength due to being overweight and complications related to being overweight, thus making activities of daily living more challenging [47].”
Obesity Pathogenesis: An Endocrine Society Scientific Statement
Schwartz, M. W., Seeley, R. J., Zeltser, L. M., Drewnowski, A., Ravussin, E., Redman, L. M., & Leibel, R. L. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00111 · Cited by 727 · cited 1×
“In addition, there is also evidence indicating that diet and exercise prompt physiological counterregulatory mechanisms that limit weight reduction and impede maintenance of lost weight [11, 12], indicating that obesity is a complex metabolic disease.”
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419 · cited 1×
“…Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) are hormones released in the intestine in response to the intake of nutrients, and they can stimulate pancreatic beta cells to release insulin, thereby participating in the regulation of glucose homeostasis [13–15].”
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388 · cited 1×
“GIP inhibits gastric secretory activity, stimulates insulin secretion, and exerts an insulin-like action on adipose tissue that inhibits lipolysis and promotes lipogenesis [39–41].”
Min, T., & Bain, S. C. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00981-0 · Cited by 285 · cited 1×
“Similar to our findings, it has been shown that Tirzepatide can improve cardiovascular risk factors such as blood pressure, waist circumference, LDL, and triglycerides [36, 37].”
Adipose tissue metabolism in obesity: Lipase action in vivo before and after a mixed meal
Coppack, S. W., Evans, R. D., Fisher, R. M., Frayn, K. N., Gibbons, G. F., Humphreys, S. M., Kirk, M. L., Potts, J. L., & Hockaday, T. D. R. (1992) · Metabolism · doi:10.1016/0026-0495(92)90269-g · Cited by 279 · cited 1×
“On the other hand, IR increases the movement of fatty acids from adipose tissue to blood circulation [44] and thus disturbs the balance of the lipid profile.”
Ethical Standards in Sport and Exercise Science Research: 2022 Update
Harriss, D. J., Jones, C., & MacSween, A. (2022) · International Journal of Sports Medicine · doi:10.1055/a-1957-2356 · Cited by 220 · cited 1×
“[ 21].”
Lopez, P., Taaffe, D. R., Galvão, D. A., Newton, R. U., Nonemacher, E. R., Wendt, V. M., Bassanesi, R. N., Turella, D. J. P., & Rech, A. (2022) · Obesity Reviews · doi:10.1111/obr.13428 · Cited by 210 · cited 1×
“In addition, exercise is associated with improved quality of life by increasing physical fitness factors, regulation of inflammation, prevention of diabetes and other diseases in people with obesity [7, 8].”
O'Donoghue, G., Blake, C., Cunningham, C., Lennon, O., & Perrotta, C. (2021) · Obesity Reviews · doi:10.1111/obr.13137 · Cited by 190 · cited 1×
“Previously, it has been demonstrated that a combination of resistance (RT) and aerobic training (AT) has more favorable effects than performing either one in isolation [9, 10].”
Signalling from the periphery to the brain that regulates energy homeostasis
Kim, K.-S., Seeley, R. J., & Sandoval, D. A. (2018) · Nature Reviews Neuroscience · doi:10.1038/nrn.2018.8 · Cited by 183 · cited 1×
“It also slows gastric emptying and induces a feeling of satiety [42].”
Waist circumference a good indicator of future risk for type 2 diabetes and cardiovascular disease
Siren, R., Eriksson, J. G., & Vanhanen, H. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-631 · Cited by 147 · cited 1×
“High BMI and waist circumference values are positively associated with T2DM and cardiovascular disease [34, 35].”
Syed, Y. Y. (2022) · Drugs · doi:10.1007/s40265-022-01746-8 · Cited by 144
Kim, S.-J., Nian, C., & McIntosh, C. H. S. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m006841 · Cited by 133
Chronic Low-Grade Inflammation in Metabolic Disorders: Relevance for Behavioral Symptoms
Lasselin, J., & Capuron, L. (2014) · Neuroimmunomodulation · doi:10.1159/000356535 · Cited by 128 · cited 1×
“Obesity increases morbidity, mortality and the risk of serious diseases such as cancer, chronic inflammation, metabolic and cardiovascular diseases [3–5].”
Overweight/Obesity and Physical Fitness Among Children and Adolescents
Dumith, S. C., Ramires, V. V., Souza, M. A., Moraes, D. S., Petry, F. G., Oliveira, E. S., Ramires, S. V., & Hallal, P. C. (2010) · Journal of Physical Activity and Health · doi:10.1123/jpah.7.5.641 · Cited by 127
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
De Block, C., Bailey, C., Wysham, C., Hemmingway, A., Allen, S. E., & Peleshok, J. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14831 · Cited by 121 · cited 1×
“Similar to our findings, it has been shown that Tirzepatide can improve cardiovascular risk factors such as blood pressure, waist circumference, LDL, and triglycerides [36, 37].”
Describing the Weight‐Reduced State: Physiology, Behavior, and Interventions
Aronne, L. J., Hall, K. D., M. Jakicic, J., Leibel, R. L., Lowe, M. R., Rosenbaum, M., & Klein, S. (2021) · Obesity · doi:10.1002/oby.23086 · Cited by 113 · cited 1×
“In addition, there is also evidence indicating that diet and exercise prompt physiological counterregulatory mechanisms that limit weight reduction and impede maintenance of lost weight [11, 12], indicating that obesity is a complex metabolic disease.”
Adverse Events Related to Tirzepatide
Mishra, R., Raj, R., Elshimy, G., Zapata, I., Kannan, L., Majety, P., Edem, D., & Correa, R. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad016 · Cited by 110 · cited 1×
“In some cases, mild hypoglycemia was also reported (22.6% of the time) [33].”
InfluentialA novel scale to assess resistance-exercise effort
Hackett, D. A., Johnson, N. A., Halaki, M., & Chow, C.-M. (2012) · Journal of Sports Sciences · doi:10.1080/02640414.2012.710757 · Cited by 109 · cited 1×
“Repetitions In Reserve (RIR) was also used to control and monitor participants’ performance [22].”
Changes in Subcutaneous Fat Cell Volume and Insulin Sensitivity After Weight Loss
Andersson, D. P., Eriksson Hogling, D., Thorell, A., Toft, E., Qvisth, V., Näslund, E., Thörne, A., Wirén, M., Löfgren, P., Hoffstedt, J., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2395 · Cited by 106 · cited 1×
“Improvements in their lipid profiles and insulin resistance may be associated with weight loss and reduction of body fat percentage [45, 46].”
Duvigneaud, N., Matton, L., Wijndaele, K., Deriemaeker, P., Lefevre, J., Philippaerts, R. M., Thomis, M. A., Delecluse, C., & Duquet, W. (2008) · PubMed · Cited by 86
Ryan, D. H. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21033 · Cited by 67 · cited 1×
“Further, a recent review by Ryan (2021) points to the development of “next-gen” antiobesity medication, such as Setmelanotide and Bimagrumab, as well as older medications, such as orlistat, liraglutide and naltrexone, that elicit weight loss for the treatment of obesity [50, 51].”
Vadher, K., Patel, H., Mody, R., Levine, J. A., Hoog, M., Cheng, A. Y., Pantalone, K. M., & Sapin, H. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14775 · Cited by 56 · cited 2×
“We present results using lower doses of Tirzepatide which may not elicit the weight loss outcomes attributed to higher doses as described by Vadher [31].”
Lift weights to fight overweight
Paoli, A., Moro, T., & Bianco, A. (2015) · Clinical Physiology and Functional Imaging · doi:10.1111/cpf.12136 · Cited by 55
Morze, J., Rücker, G., Danielewicz, A., Przybyłowicz, K., Neuenschwander, M., Schlesinger, S., & Schwingshackl, L. (2021) · Obesity Reviews · doi:10.1111/obr.13218 · Cited by 55
Ryan, D. H. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_560 · Cited by 42 · cited 1×
“Further, a recent review by Ryan (2021) points to the development of “next-gen” antiobesity medication, such as Setmelanotide and Bimagrumab, as well as older medications, such as orlistat, liraglutide and naltrexone, that elicit weight loss for the treatment of obesity [50, 51].”
Bagherzadeh-Rahmani, B., Kordi, N., Haghighi, A. H., Clark, C. C. T., Brazzi, L., Marzetti, E., & Gentil, P. (2022) · Sports Health A Multidisciplinary Approach · doi:10.1177/19417381221124601 · Cited by 32 · cited 1×
“In addition, exercise is associated with improved quality of life by increasing physical fitness factors, regulation of inflammation, prevention of diabetes and other diseases in people with obesity [7, 8].”
Self-citationBulum, T. (2022) · Biomedicines · doi:10.3390/biomedicines10102586 · Cited by 31
Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis
Karrar, H. R., Nouh, M. I., Nouh, Y. I., Nooh, M. I., Alhindi, A. S. K., Hemeq, Y. H., Aljameeli, A. M. S., Aljuaid, J. A., Alzahrani, S. J., Alsatami, A. A., et al. (2023) · Cureus · doi:10.7759/cureus.46091 · Cited by 31 · cited 1×
“However, these larger doses are also attributed to gastrointestinal manifestations, namely nausea, vomiting, decreased appetite, dyspepsia, constipation and diarrhea [32].”
Martínez‐Ramírez, M., Madero, M., Vargas‐Alarcón, G., Vargas‐Barrón, J., Fragoso, J. M., Rodrı́guez-Pérez, J. M., Martínez‐Sánchez, C., González‐Pacheco, H., Bautista‐Pérez, R., Carreón‐Torres, E., et al. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.12.039 · Cited by 21
Yu, Y., Hu, G., Yin, S., Yang, X., Zhou, M., & Jian, W. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.990182 · Cited by 17 · cited 1×
“Tirzepatide injection was administered subcutaneously in the abdomen by a physician once a week using doses of 2.5 mg and 5 mg on a day when the subject did not exercise [25, 26].”
InfluentialLilly’s tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimetics
Mullard, A. (2022) · Nature Reviews Drug Discovery · doi:10.1038/d41573-022-00094-2 · Cited by 11 · cited 1×
“The Food and Drug Administration (FDA) approved Tirzepatide for use once per week using subcutaneous injections as monotherapy or with diet and physical exercise, in patients affected by Type 2 diabetes mellitus (T2DM) [17, 18].”
Cited by
Karakasis, P., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156113 · Cited by 242
Integrating diet and physical activity when prescribing GLP-1s—Lifestyle factors remain crucial
Mehrtash, F., Dushay, J., & Manson, J. E. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.1794 · Cited by 44
Rochira, V., Greco, C., Boni, S., Costantino, F., Dalla Valentina, L., Zanni, E., Itani, L., & El Ghoch, M. (2024) · Diseases · doi:10.3390/diseases12090204 · Cited by 34
“…were on medications other than TZP that might interfere with body weight and BC [20,21,34–45]; (ii) two due to the short duration of the TZP treatment [46,47]; (iii) one because it had an open-label lead-in period [48]; and (iv) five for not reporting data related to WC [49–53] (Figure 1).”
BackgroundProkopidis, K. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70355 · Cited by 29
Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition: A Systematic Review
Batsis, J. A., Gavras, A., Gross, D. C., Cheever, C. R., da Silva, B. R., Filho, L. F. M., Jones, E. P., Batchek, D. J., Khandpekar, S. G., Patel, R., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-00478 · Cited by 34
Metadata
- Authors
- Bagherzadeh-Rahmani, B., Marzetti, E., Karami, E., Campbell, B. I., Fakourian, A., Haghighi, A. H., Mousavi, S. H., Heinrich, K. M., Brazzi, L., Jung, F., Baker, J. S., & Patel, D. I.
- Affiliations
- Hakim Sabzevari University (IR)
- Università Cattolica del Sacro Cuore (IT)
- Aja University of Medical Sciences (IR)
- University of South Florida (US)
- Islamic Azad University, Tehran (IR)
- Kansas State University (US)
- University of Turin (IT)
- Brandenburg University of Technology Cottbus-Senftenberg (DE)
- Hong Kong Baptist University (HK)
- The University of Texas Medical Branch at Galveston (US)
- Corresponding author
- Bagherzadeh-Rahmani, Behnam
- ORCID
- Venue
- Clinical Hemorheology and Microcirculation
- Publisher
- SAGE Publications
- Published
- 2024-04-12
- Volume
- 87
- Issue
- 4
- Pages
- 465-480
- ISSN
- 1386-0291 (ISSN-L)
- 1875-8622
- OpenAlex
- W4394838417
- Semantic Scholar
- 3af0754f947c8a94b3169e1d6895bfa333f91908
- Cited by
- 21
- References
- 51
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 4
- FWCI
- 6.87
- Type
- journal article
- Language
- en
- Status
- Retracted
- Update notices
- retraction (2025-11-23)
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Clinical Hemorheology and Microcirculation (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Physical Activity and Health
- Keywords
- GIP/GLP-1 receptor agonist, tirzepatide, obesity, prediabetes, resistance training, aerobic exercise, concurrent training, lipid profile, insulin resistance, body composition, cardiorespiratory fitness, muscle strength, military personnel, retracted article
- MeSH terms
- Adult, Humans, Insulin Resistance, Male, Obesity, Exercise, Body Mass Index, Resistance Training
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.